摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-{4-[5-(2,5-Dimethyl-phenyl)-3,6-diethyl-pyrazin-2-yl]-3,5-dimethoxy-phenyl}-ethanone | 478035-88-0

中文名称
——
中文别名
——
英文名称
1-{4-[5-(2,5-Dimethyl-phenyl)-3,6-diethyl-pyrazin-2-yl]-3,5-dimethoxy-phenyl}-ethanone
英文别名
1-[4-[5-(2,5-Dimethylphenyl)-3,6-diethylpyrazin-2-yl]-3,5-dimethoxyphenyl]ethanone
1-{4-[5-(2,5-Dimethyl-phenyl)-3,6-diethyl-pyrazin-2-yl]-3,5-dimethoxy-phenyl}-ethanone化学式
CAS
478035-88-0
化学式
C26H30N2O3
mdl
——
分子量
418.536
InChiKey
WUZIDBVQKLRIPB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    494.2±45.0 °C(Predicted)
  • 密度:
    1.089±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    61.3
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines
    申请人:Neurogen Corporation
    公开号:US20030119844A1
    公开(公告)日:2003-06-26
    Diarylpyrazine, diarylpyridine, and diarylpyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of Formula I are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    提供作为CRF 1受体选择性调节剂的Diarylpyrazine、diarylpyridine和diarylpyrimidine化合物。这些化合物对治疗多种中枢神经系统和外周疾病特别有效,包括压力、焦虑、抑郁、心血管疾病和进食障碍。还提供了治疗这些疾病的方法以及包装的药物组合物。Formula I的化合物也可用作CRF受体的定位探针和CRF受体结合测定中的标准。给出了使用这些化合物进行受体定位研究的方法。
  • Novel compounds useful as reversible inhibitors of cysteine proteases
    申请人:——
    公开号:US20020137932A1
    公开(公告)日:2002-09-26
    Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds. 1
    揭示了一种新型的cathepsin S、K、F、L和B的可逆抑制化合物,其化学式为(Ia)和(Ib),其中R2、R3、R4、R5、R6、R7、R8、Het和X的定义如下。这些化合物可用于治疗自身免疫和其他疾病。还公开了制备这种新型化合物的方法。
  • Compounds useful as reversible inhibitors of cysteine proteases
    申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
    公开号:US20030216383A1
    公开(公告)日:2003-11-20
    Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds. 1
    本发明揭示了一种新的cathepsin S、K、F、L和B可逆抑制化合物,其化学式为(Ia)和(Ib),其中R2、R3、R4、R5、R6、R7、R8、Het和X的定义如下。这些化合物对于治疗自身免疫和其他疾病非常有用。本发明还揭示了制备这种新化合物的方法。
  • 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines
    申请人:Huang Jianhua
    公开号:US20050176721A1
    公开(公告)日:2005-08-11
    Diarylpyrazine, diarylpyridine, and diarylpyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of Formula I are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    提供了作为CRF 1 受体选择性调节剂的二芳基吡嗪、二芳基吡啶和二芳基嘧啶化合物。这些化合物在治疗许多中枢神经系统和周围疾病,特别是压力、焦虑、抑郁、心血管疾病和进食障碍方面具有用途。还提供了治疗这些疾病的方法以及包装的制药组合物。公式 I 的化合物也可用作CRF受体定位的探针,以及CRF受体结合测定中的标准。给出了使用这些化合物进行受体定位研究的方法。
  • SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES
    申请人:BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
    公开号:EP1322613A1
    公开(公告)日:2003-07-02
查看更多